At King Faisal Specialist Hospital & Research Centre (KFSHRC), the treatment of drug-resistant epilepsy has developed over decades into a comprehensive clinical program that combines advanced ...
Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...
SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic ...
The Trump administration is soon expected to propose a plan that would cap loans for a number of advanced degrees—including master’s and doctoral degrees in nursing—and it’s gone viral on social media ...
A landmark multi-country clinical trial has shown that a structured, sustainable approach to infection prevention and treatment can save women's lives, cutting severe maternal infections and deaths by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback